ITL BioMedical, a division of ITL Health Group (ASX:ITD), that sets industry standards for the innovative design and production of biological sampling systems, is pleased to announce that the Pró-Sangue blood center in Brazil has begun using ITL’s SampLok® Sampling Kit (SSK).
Continue reading “Largest South American Blood Center Initiates Use of ITL’s SSK”
ITL Health Group (ASX:ITD), is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, has been awarded a $2.6m CRC-Project grant for the development of new health testing methods using dried blood spot samples. Continue reading “MyHealthTest awarded $2.6m CRC Project Grant”
ITL Health Group is pleased to provide the opportunity to listen to an audio interview with Mr. Bill Mobbs, Executive Chairman.
Continue reading “Boardroom Media Interview: Positive Full Year Results Expected”
ITL Health Group (“ITL”), an innovative global medical technology company, expects to announce very positive results for the financial year to 30 June 2017. Continue reading “ITL Announces Positive Full Year Trading Update”
MyHealthTest (MHT), a division of ITL Health Group (ASX:ITD) that creates and markets highly innovative direct to consumer pathology testing for major chronic diseases, is very pleased to announce it has been granted accreditation for its testing laboratory to the ISO15189 and NPAAC (National Pathology Accreditation Advisory Council) standards by the National Association of Testing Authorities (NATA) and the Royal College of Pathologists of Australasia (RCPA).
Continue reading “MyHealthTest Achieves Major Milestone of Laboratory Accreditation”
ITL Health Group (ASX:ITD), an innovative global medical technology company, is pleased to announce that in February the Company recorded its highest monthly revenue and profit in its 23-year history. ITL BioMedical and ITL Healthcare both achieved record months. Continue reading “ITL Achieves Record Month”
ITL Limited (ASX:ITD), an innovative global medical technology company, supplier and strategic partner that provides innovative products and solutions to healthcare markets and empowers individual health management, formally announces its rebrand to ITL Health Group (ITL).
Continue reading “ITL Limited Rebrands to ITL Health Group to Unify Divisions under a Global Brand”
Following the strong first half results announced on Friday 17th February the company is issuing the following presentation – “Half year results 2016/17 and ITL BioMedical Growth Update” – in order to provide greater insight into ITL’s innovative products range and the exciting growth opportunities in the BioMedical division.
Continue reading “ITL Half Year Results and BioMedical Growth Update”
ITL Limited is pleased to provide the opportunity to listen to an audio interview with Mr Bill Mobbs, Executive Chairman.
Mr Mobbs talks about the Company’s strong first half results that saw revenue rise 11%, EBITDA up 69% and profit before tax grow 110% versus the previous comparative period, and provides an insight into ITL’s innovative products range and the exciting growth opportunities in the BioMedical division.
Continue reading “Boardroom Media Interview: Strong Half Year Results and ITL BioMedical Update”
ITL Limited (“ITL”), an innovative diversified healthcare company, is pleased to announce excellent results for the half year ended 31 December 2016 compared with the previous corresponding period.
Continue reading “ITL Profit Doubles in Half Year 2016-17 Results”
